3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione has been researched along with etoposide in 2 studies
| Studies (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Trials (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Recent Studies (post-2010) (3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione) | Studies (etoposide) | Trials (etoposide) | Recent Studies (post-2010) (etoposide) |
|---|---|---|---|---|---|
| 49 | 7 | 8 | 18,306 | 3,693 | 4,900 |
| Protein | Taxonomy | 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione (IC50) | etoposide (IC50) |
|---|---|---|---|
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | 1.153 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 1.4284 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 3.187 | |
| Caspase-3 | Homo sapiens (human) | 1 | |
| DNA topoisomerase 2-beta | Homo sapiens (human) | 0.4299 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Arsenau, JC; Blessing, J; Lewis, GC; Slavik, M | 1 |
2 other study(ies) available for 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione and etoposide
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Etoposide; Female; Humans; Maytansine; Neoplasm Recurrence, Local; Pelvic Neoplasms; Piperazines; Razoxane; Research Design; Triazines | 1982 |